This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.
Male or female participants aged ≥18 years.
Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
Psychiatric disorders or other conditions that may affect participant safety or compliance.
Pregnant or breastfeeding women.
Institute of Dermatology, Thailand
Lead sponsor
MEDEZE Cosmeceutical Company Limited
Collaborator